Trial ID or NCT#



recruiting iconRECRUITING


This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with documented BRAF V600 mutation and locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in Part A, or in combination with cobimetinib (Cotellic®) in Part B in adult patients who also have documented progressive disease or intolerance to previous combination treatment of BRAF and MEK inhibitors. A "3+3" design will be used to determine MTD and RP2D.

Official Title

A Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310, Administered Orally in Adult Patients With Advanced Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Seema Nagpal, MD
Seema Nagpal, MD
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.


Priya Yerraballa